![Huma Qamar](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 6 122 $ al 31/05/2026
Huma Qamar formerly worked at Ocugen, Inc., as Chief Medical Officer from 2024 to 2026, Quantum BioPharma Ltd., as Head-Research & Development, and Medicus Pharma Ltd., as Chief Scientific Officer from 2023 to 2024.
Dr. Qamar received her doctorate degree from Army Medical College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
OCUGEN INC 0 % | 20/04/2026 | 4.436 ( 0 % ) | 6 122 $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| OCUGEN, INC. | Director Técnico/Científico/I+D | 08/05/2026 |
| QUANTUM BIOPHARMA LTD. | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 3 |
|---|---|
Army Medical College
 Army Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FSD Pharma, Inc.
 FSD Pharma, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurodegenerative, inflammatory and metabolic disorders | Health Technology |
Ocugen, Inc.
 Ocugen, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes gene therapy products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
